|
Clinic visit
|
NFATP
|
Frequency of patient's visits at an HIV clinic in the past six months for ART drug refill
|
Two or more in the past six months
|
|
Routine test
|
NFATP
|
Frequency of respondent's free routine testing including simple renal function (i.e., plasma creatinine, urea), liver function (i.e., alanine aminotransferase and aspartate aminotransferase), complete blood cell counts in the last 12 months for monitoring toxicity of ART
|
Four or more in the past 12 months
|
|
CD4 count
|
NFATP and outpatient system
|
Frequency of respondent's CD4 testing in the last 12 months for immunological monitoring
|
For counts between 300 and 500 cells/mm3, receiving at least one test in the last 12 months, and for counts less than 300 cells/mm3, receiving at least two tests in the last 12 months [12, 34]
|
|
Viral load assay
|
NFATP and outpatient system
|
Frequency of respondent's viral load assay in the last 12 months for virological monitoring
|
At least twice in the last 12 months [12, 34]
|
|
Mental health assessment
|
Self-report
|
Respondent's answer to the question "Have you received a mental health assessment from a health provider in the last 12 months?" with "Yes" or "No"
|
Received in the last 12 months
|
|
Mental health counseling
|
Self-report
|
Respondent's answer to the question "Have you received mental health counseling from a health provider in the last 12 months?" with "Yes" or "No"
|
Received in the last 12 months
|
|
BMD
|
Outpatient system
|
Whether the respondent had a lumbar spine and femur BMD by dual-energy X-ray absorptiometry scanner in the last 12 months
|
Received in the last 12 months
|
|
Evaluation of CKD risk
|
Outpatient system
|
Whether the respondent received evaluation of the risk of CKD, including calculation of creatinine clearance (Cockcroft-Gault' formula), urinalysis with urine glucose, urine protein and urinary β 2-microglobulin in the last 12 months
|
Received in the last 12 months
|
|
Monitoring CVD risk
|
Outpatient system
|
Whether the respondent received measurement of blood lipids and blood pressure for monitoring risk of CVD in the last 12 months
|
Received in the last 12 months
|
|
ECG
|
Outpatient system
|
Whether the respondent had an ECG in the last 12 months
|
Received in the last 12 months
|
|
TB screening
|
Outpatient system
|
Whether the respondent had a chest X-ray and further sputum smear in the last 12 months
|
Received in the last 12 months
|
|
Hepatitis B serologic testing
|
Outpatient system
|
Whether the respondent had testing of HBV antigen and antibody, or HBV-DNA in the last 12 months
|
Received in the last 12 months
|
|
Hepatitis C serologic testing
|
Outpatient system
|
Whether the respondent had testing for anti-HCV, HCV-RNA, or other HCV genotype in the last 12 months
|
Received in the last 12 months
|
|
Syphilis serological testing
|
Outpatient system
|
Whether the respondent had testing a nontreponemal test (i.e., RPR) and a treponemal test (i.e., the TP-PA) in the last 12 months
|
Received in the last 12 months
|
